Dr. Brufsky Discusses Pertuzumab in HER2+ Breast Cancer

Adam M. Brufsky, MD, PhD
Published Online: Monday, Nov 13, 2017



Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
 


Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses pertuzumab (Perjeta) in HER2-positive breast cancer.

Brufsky says that the approval of pertuzumab would really only change dosing, as many clinicians are already using the drug to treat patients with HER2-positive breast cancer.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x